Targeting the mevalonate pathway in multiple myeloma

被引：3
作者：
van der Spek, Ellen [1 ]
机构：
[1] Univ Med Ctr Utrecht, Dept Hematol, NL-3584 CX Utrecht, Netherlands
来源：
LEUKEMIA RESEARCH | 2010年 / 34卷 / 03期
关键词：
Multiple myeloma; Mevalonate pathway; Plasma cell lines; FPP; GGPP; CELL-LINES; DRUG-RESISTANCE; PLASMA-CELLS; APOPTOSIS; SIMVASTATIN; INHIBITOR; SURVIVAL; PROTEIN; GERANYLGERANYLATION; FARNESYLATION;
D O I：
10.1016/j.leukres.2009.07.027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：267 / 268
页数：2
相关论文
共 23 条
[1]   Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma [J].
Alsina, M ;
Fonseca, R ;
Wilson, EF ;
Belle, AN ;
Gerbino, E ;
Price-Troska, T ;
Overton, RM ;
Ahmann, G ;
Bruzek, LM ;
Adjei, AA ;
Kaufmann, SH ;
Wright, JJ ;
Sullivan, D ;
Djulbegovic, B ;
Cantor, AB ;
Greipp, PR ;
Dalton, WS ;
Sebti, SM .
BLOOD, 2004, 103 (09) :3271-3277
[2]   Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma [J].
Attal, Michel ;
Harousseau, Jean-Luc ;
Leyvraz, Serge ;
Doyen, Chantal ;
Hulin, Cyrille ;
Benboubker, Lofti ;
Agha, Ibrahim Yakoub ;
Bourhis, Jean-Henri ;
Garderet, Laurent ;
Pegourie, Brigitte ;
Dumontet, Charles ;
Renaud, Marc ;
Voillat, Laurent ;
Berthou, Christian ;
Marit, Gerald ;
Monconduit, Mathieu ;
Caillot, Denis ;
Grobois, Bernard ;
Avet-Loiseau, Herve ;
Moreau, Philippe ;
Facon, Thierry .
BLOOD, 2006, 108 (10) :3289-3294
[3]   Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma [J].
Berenson, JR ;
Lichtenstein, A ;
Porter, L ;
Dimopoulos, MA ;
Bordoni, R ;
George, S ;
Lipton, A ;
Keller, A ;
Ballester, O ;
Kovacs, MJ ;
Blacklock, HA ;
Bell, R ;
Simeone, J ;
Reitsma, DJ ;
Heffernan, M ;
Seaman, J ;
Knight, RD .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (08) :488-493
[4]   The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells [J].
Bolick, SCE ;
Landowski, TH ;
Boulware, D ;
Oshiro, MM ;
Ohkanda, J ;
Hamilton, AD ;
Sebti, SD ;
Dalton, WS .
LEUKEMIA, 2003, 17 (02) :451-457
[5]   Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells [J].
Cafforio, P ;
Dammacco, F ;
Gernone, A ;
Silvestris, F .
CARCINOGENESIS, 2005, 26 (05) :883-891
[6]   Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation [J].
Dai, Yun ;
Khanna, Payal ;
Chen, Shuang ;
Pei, Xin-Yan ;
Dent, Paul ;
Grant, Steven .
BLOOD, 2007, 109 (10) :4415-4423
[7]   REGULATION OF THE MEVALONATE PATHWAY [J].
GOLDSTEIN, JL ;
BROWN, MS .
NATURE, 1990, 343 (6257) :425-430
[8]   The effect of statin use at the time of autologous transplant on response and survival in multiple myeloma [J].
Hamadani, Mehdi ;
Hade, Erinn ;
Benson, Don M. ;
Hofineister, Craig C. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (03) :351-352
[9]   Sterol-independent regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in tumor cells [J].
Hentosh, P ;
Yuh, SH ;
Elson, CE ;
Peffley, DM .
MOLECULAR CARCINOGENESIS, 2001, 32 (03) :154-166
[10]   Risk of multiple myeloma following medication use and medical conditions: A case-control study in Connecticut women [J].
Landgren, Ola ;
Zhang, Yawei ;
Zahm, Sheila Hoar ;
Inskip, Peter ;
Zheng, Tongzhang ;
Baris, Dalsu .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (12) :2342-2347
123